← All trials
NCT05476939
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2022
- Primary completion
- Sep 30, 2028
- Completion date
- Sep 30, 2031
- First posted
- Jul 27, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 368
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institut Gustave RoussyLead sponsor
- ChimerixCollaborator
- Institut Gustave RoussyStudy chair
- Innovative Therapies For Children with Cancer ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.